NCT04087174View on ClinicalTrials.gov

A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

August 5, 2019

Primary Completion Date

June 22, 2021

Study Completion Date

June 22, 2021

Conditions
Prostate Cancer
Interventions
DRUG

Capivasertib

Patients will receive multiple oral dose of capivasertib.

DRUG

Enzalutamide

Patients will receive 160 mg oral dose of enzalutamide.

DRUG

Abiraterone

Patients will receive 1000 mg oral dose of abiraterone.

Trial Locations (6)

10601

Research Site, White Plains

17325

Research Site, Gettysburg

29572

Research Site, Myrtle Beach

46202

Research Site, Indianapolis

68114

Research Site, Omaha

08036

Research Site, Barcelona

Sponsors

Lead Sponsor

AstraZeneca

Collaborators (1)

Parexel
All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY

NCT04087174 - A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer | Biotech Hunter | Biotech Hunter